MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
AgeX Therapeutics Total Current Liabilities 2011-2026 | AGE
Annual Total Current Liabilities AgeX Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.91 M | 10.1 M | 8.97 M | 5.36 M | 3.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 3.3 M | 6.72 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
25.5 B | $ 349.77 | 0.57 % | $ 188 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Altimmune
ALT
|
15 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.4 | 2.19 % | $ 357 M |  Britain |
 |
Aytu BioScience
AYTU
|
63.1 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
Benitec Biopharma
BNTC
|
1.8 M | $ 11.19 | 1.91 % | $ 461 M | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | USA |
 |
Compugen Ltd.
CGEN
|
22.6 M | $ 2.09 | - | $ 195 M |  Israel |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M |  Canada |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.97 M | $ 0.61 | -1.3 % | $ 6.99 M | Israel |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
37.7 M | $ 12.84 | 0.78 % | $ 774 M | USA |
 |
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
174 M | $ 6.42 | 2.72 % | $ 462 K | USA |
 |
Cara Therapeutics
CARA
|
25.6 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
125 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Denali Therapeutics
DNLI
|
102 M | $ 21.09 | 4.56 % | $ 3.47 B | USA |
 |
Dyadic International
DYAI
|
2.25 M | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | USA |